Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Camrelizumab +/- TPF in OSCC
NCT04649476Phase 2Completed
- Start
- Mar 2021
- Primary completion
- Aug 2022
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in oral squamous cell carcinoma (OSCC). Started Mar 2021; status: completed.
02
Drugs
camrelizumab
03
Conditions
oral squamous cell carcinoma (OSCC)
Beyond the preview
Go deeper on NCT04649476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04649476.